Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...

DXD Capital expects cautious optimism to replace the current prudence in the self storage lending environment, according to Bailey. Photo by Frankie Gomez Gallery, courtesy of DXD Capital Lending ...

Raludotatug deruxtecan (R-DXd) targets CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers, offering a novel treatment option for patients with limited ...

KNOXVILLE, TN, UNITED STATES, July 15, 2025 /EINPresswire.com/ -- DXD Capital, in partnership with Olympus Ventures LLC, is pleased to announce the groundbreaking of ...

When Merck & Co. and Daiichi Sankyo last year received an FDA complete response letter for their HER3-directed antibody-drug conjugate (ADC) patritumab deruxtecan, the companies hoped to address ...

IDeate-PanTumor02: A phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients (pts) with recurrent or metastatic solid tumors. This is an ASCO Meeting Abstract ...

High School DxD culminates with Issei Hyoudou and Rias Gremory solidifying their bond. Issei's growth into a powerful devil earns him recognition alongside Rias, leading to their official engagement.

High School DxD fans are waiting for Season 5. The anime series has a strong following. It blends comedy with supernatural action. Issei Hyoudou's story continues in manga and light novels. These ...

New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...

High School DxD season 5 has been on the anime community's radar for a while now, with several rumors circulating regarding the sequel's production. Previously, some insider sources suggested the 2024 ...

During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article ...